Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
-
Busy address KBO
20 other companies have their registered office at the same address; threshold 10.
Financials
Financial year 2025
Labophar from Gent, company number BE0643723177, closed financial year 2025 with a result of € -375,714 after tax. For that financial year Labophar recorded revenue of € 406,703 and equity of € 2.5 million. Compared with financial year 2024, the result moved from € -417,897 to € -375,714. The company made a loss. The company holds a healthy buffer. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on June 30, 2026.
€ 2.5 million
▼ 13% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -375,714
▲ 10 % less loss than in 2024
Profit after tax over the fiscal year.
Loss, nothing to pay out
Reserves fell to € -2.1 million.
People and assets in 2025
€ 4,918
▼ 79% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 4 million
Loans from banks and other lenders, long and short.
€ 40,311
▼ 43% vs 2024
Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 650 days on average.
€ 165,126
▲ 236% vs 2024
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Revenue | € 4,412,659 | € 1,478,114 | € 407,526 | € 406,703 | |
| Profit after taxes | € -511,299 | € -463,149 | € -417,897 | € -375,714 | ▲ € 42,183 |
| Equity | € 3,734,582 | € 3,271,433 | € 2,853,536 | € 2,477,822 | ▼ 13% |
| Total debts | € 7,198,586 | € 5,539,203 | € 5,761,483 | € 6,171,338 | ▲ 7% |
| Cash | € 313,006 | € 0 | - | - | |
| Retained profit | € -876,032 | € -1,339,181 | € -1,757,078 | € -2,132,792 | ▼ € 375,714 |
| Bank debt | € 0 | € 0 | € 0 | € 3,974,155 | |
| Balance sheet total | € 11,175,992 | € 8,810,636 | € 8,615,019 | € 8,649,159 | |
| Employees (FTE) | 11.7 | 0 | - | - |
Key figures of Labophar, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to Labophar?
What happened at Labophar in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- AQUITANIA BV stepped down as director. NBB
- CREDOPHAR BV stepped down as director. NBB
- FARMAFENDER BV stepped down as director. NBB
- New annual accounts for financial year 2025: loss of € 375,714. Source: NBB ↗
- AQUITANIA BV became a director. NBB
- CREDOPHAR BV became a director. NBB
- FARMAFENDER BV became a director. NBB
- New establishment in Gent. KBO
In short
From € 511,299 loss in 2022 to € 375,714 loss in 2025.
Paid € 114,904 in corporate taxes since 2022.
A new publication or filing at Labophar? We notify you, reason included.
Follow LabopharDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The shares are held by CREDOPHAR (100%). It owns 100% of DGPharma and 100% of b+pharma Belgium itself.
Directors
According to the 2025 annual accounts
Director · represented by ANJA IMSCHOOT
Also active at: Ceres Pharmaceuticals, VESALE PHARMACEUTICA, b+pharma Belgium, DGPharma, 2PHARMA HOLDING, MD Pharma, GLOBIFER INTL, CREDOPHAR +1 more
since 2022 · until 2028
since 2022 · until 2028
Managing director · represented by BRAM VAN PETEGHEM
Also active at: b+pharma Belgium, DGPharma
since 2022 · until 2028
Shareholders
100%
Participations
100%
100%
Establishments
Establishment units
Physical locations of this company
Kortrijksesteenweg 1091 box B
9051 Gent
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 20 companies are registered at this address.
All companies at this address →Ceres Pharmaceuticals same network
€ 14.6 million revenue · 2025
What's Cooking Group
KOUTERLOS
€ 55,337 gross margin · 2024
b+pharma Belgium same network
€ 287,023 gross margin · 2025
DGPharma same network
€ 94,120 gross margin · 2024
+15 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0643.723.177
- VAT number
- BE 0643.723.177
- Registered office
- Kortrijksesteenweg 1091 bus B, 9051 Gent
- Names & denominations
- Labophar
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 30 November 2015
- Peppol
- Active · Active since 1 Aug 2025
- Activities · NACE
Handel in eigen onroerend goed
Detailhandel in farmaceutische producten
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Groothandel in farmaceutische en medische artikelen
Overige technische testen en toetsen
Detailhandel in medische en orthopedische artikelen, muv corrigerende brillen, lenzen en zonnebrillen
Detailhandel in medische en orthopedische artikelen in gespecialiseerde winkels
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied